Infection with Leishmania parasites results in a range of clinical manifestations and
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …

Leishmaniasis is a neglected disease resulting in a global morbidity of 2,090 thousand
Disability‐Adjusted Life Years and a mortality rate of approximately 60,000 per year. Among …

Therapeutic vaccines, when used alone or in combination therapy with antileishmanial
drugs, may have an important place in the control of a variety of forms of human …

Numerous experimental Leishmania vaccines have been developed to prevent the visceral
and cutaneous forms of Leishmaniasis, which occur after exposure to the bite of an infected …

Background Recombinant KSAC and L110f are promising Leishmania vaccine candidates.
Both antigens formulated in stable emulsions (SE) with the natural TLR4 agonist MPL® and …

The field of “One Health” encourages researchers to collaborate across a wide range of
disciplines to improve health at the animal-human-ecosystems interface. One Health …

Leishmaniasis is a major health problem and it is estimated that 12 million people are
currently infected. A vaccine which could cross-protect people against different Leishmania …

Numerous experimental Leishmania vaccines have been developed to prevent the visceral
and cutaneous forms of Leishmaniasis, which occur after exposure to the bite of an infected …

Conclusions: L. infantum upon continuous subculture rapidly looses virulence through a
process related to the incapacity to differentiate into amastigotes.Page 90 …

Cutaneous leishmaniasis is endemic in tropical and subtropical regions of the world.
Effective vaccination strategies are urgently needed because of the emergence of drug …